Diosgenin (Synonyms: 薯蕷皂素)

目錄號: HY-N0177 純度: 99.35%: FAQs
Data Sheet SDS COA 產(chǎn)品使用指南技術支持

Diosgenin，一種甾體皂苷，能夠抑制 STAT3 信號通路。Diosgenin 是 Pdia3/ERp57 的激活劑。Diosgenin 通過抑制巨噬細胞 miR-19b 表達抑制主動脈粥樣硬化進展。

MCE 的所有產(chǎn)品僅用作科學研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務

Diosgenin Chemical Structure

CAS No. : 512-04-9

1. 客戶無需承擔相應的運輸費用。

2. 同一機構（單位）同一產(chǎn)品試用裝僅限申領一次，同一機構（單位）一年內

可免費申領三個不同產(chǎn)品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價格	是否有貨
100 mg	￥350	In-stock
500 mg	￥560	In-stock
1 g		詢價
5 g		詢價

or 大包裝詢價

* Please select Quantity before adding items.

Customer Review

Other Forms of Diosgenin:

Diosgenin glucoside In-stock
Diosgenin (Standard) 詢價

MCE 顧客使用本產(chǎn)品發(fā)表的 5 篇科研文獻

•J Biomed Sci. 2023 Jun 27;30(1):44. [Abstract]
•Phytomedicine. 2024 Jan 20, 155299.
•Biochem Biophys Res Commun. 2024 Apr 17:712-713:149941. [Abstract]
•Authorea. May 12, 2022.
•Cell Physiol Biochem. 2016;39(4):1626-37. [Abstract]

Proliferation Assay

: Diosgenin purchased from MCE. Usage Cited in: Cell Physiol Biochem. 2016;39(4):1626-37. [Abstract]; Arithmetic means ± SEM (n = 10) of erythrocyte annexin-V-binding following incubation for 48 hours to Ringer solution without (white bar) or with (black bars) Diosgenin (5-15 μM).

Diosgenin 相關產(chǎn)品

•相關化合物庫:

•同靶點產(chǎn)品:

•同靶點蛋白產(chǎn)品:

查看 STAT 亞型特異性產(chǎn)品:

查看所有亞型

STAT3 STAT5 STAT6 STAT1

生物活性
純度 & 產(chǎn)品資料
參考文獻

生物活性

Diosgenin, a steroidal saponin, can inhibit STAT3 signaling pathway^[1]. Diosgenin is an exogenous activator of Pdia3/ERp57^[2]. Diosgenin inhibits aortic atherosclerosis progression by suppressing macrophage miR-19b expression^[5].

IC₅₀ & Target^[1]

STAT3

細胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 10 μM Compound: 1	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 33381964]
A549	IC₅₀	> 20 μM Compound: a1	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
A549	IC₅₀	10.8 μM Compound: Diosgenin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
A549	IC₅₀	26.41 μM Compound: Diosgenin	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31761382]
A549	IC₅₀	32.85 μM Compound: DSG; 1	Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 33740546]
ASPC1	IC₅₀	63.11 μM Compound: Diosgenin	Antiproliferative activity against human ASPC1 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human ASPC1 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 35586422]
BXPC-3	GI₅₀	1 μg/mL Compound: 7	Growth inhibition of humanBxPC3 cells after 48 hrs Growth inhibition of humanBxPC3 cells after 48 hrs	[PMID: 15921418]
DU-145	GI₅₀	8.5 μg/mL Compound: 7	Growth inhibition of human DU145 cells after 48 hrs Growth inhibition of human DU145 cells after 48 hrs	[PMID: 15921418]
GES1	IC₅₀	100.7 μM Compound: Diosgenin	Cytotoxicity against human GES1 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human GES1 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31761382]
HBL-100	IC₅₀	10.8 μM Compound: Diosgenin	Antiproliferative activity against human HBL100 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HBL100 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
HCT-116	IC₅₀	10.8 μM Compound: Diosgenin	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
HCT-116	IC₅₀	31.41 μM Compound: Diosgenin	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 35586422]
HCT-116	IC₅₀	49.11 μM Compound: Diosgenin	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31761382]
HeLa	IC₅₀	> 50 μg/mL Compound: 21	Cytotoxicity against human HeLa cells after 6 days by SRB assay Cytotoxicity against human HeLa cells after 6 days by SRB assay	[PMID: 22880631]
HepG2	IC₅₀	> 10 μM Compound: 1	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 33381964]
HepG2	IC₅₀	> 50 μM Compound: 1, Diosgenin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23153797]
HepG2	IC₅₀	33.87 μM Compound: Diosgenin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31761382]
HepG2	IC₅₀	48.36 μM Compound: DSG; 1	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 33740546]
HL-60	IC₅₀	> 20 μM Compound: a1	Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
HT-29	IC₅₀	> 50 μg/mL Compound: 21	Cytotoxicity against human HT-29 cells after 6 days by SRB assay Cytotoxicity against human HT-29 cells after 6 days by SRB assay	[PMID: 22880631]
HT-29	IC₅₀	10.8 μM Compound: Diosgenin	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
K562	IC₅₀	> 50 μg/mL Compound: 21	Cytotoxicity against human K562 cells after 6 days by SRB assay Cytotoxicity against human K562 cells after 6 days by SRB assay	[PMID: 22880631]
K562	IC₅₀	30.04 μM Compound: DSG; 1	Cytotoxicity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 33740546]
KM-20L2	GI₅₀	1.1 μg/mL Compound: 7	Growth inhibition of human KM20L2 cells after 48 hrs Growth inhibition of human KM20L2 cells after 48 hrs	[PMID: 15921418]
MCF7	IC₅₀	> 10 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 33381964]
MCF7	IC₅₀	> 20 μM Compound: a1	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
MCF7	IC₅₀	> 50 μg/mL Compound: 21	Cytotoxicity against human MCF7 cells after 6 days by SRB assay Cytotoxicity against human MCF7 cells after 6 days by SRB assay	[PMID: 22880631]
MCF7	GI₅₀	0.42 μg/mL Compound: 7	Growth inhibition of human MCF7 cells after 48 hrs Growth inhibition of human MCF7 cells after 48 hrs	[PMID: 15921418]
MCF7	IC₅₀	23.91 μM Compound: Diosgenin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31761382]
MCF7	IC₅₀	28.52 μM Compound: DSG; 1	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 33740546]
MDA-MB-231	IC₅₀	> 50 μM Compound: 1, Diosgenin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 23153797]
MKN-45	IC₅₀	78.32 μM Compound: DSG; 1	Cytotoxicity against human MNK45 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against human MNK45 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 33740546]
MM96L	IC₅₀	> 50 μg/mL Compound: 21	Cytotoxicity against human MM96L cells after 6 days by SRB assay Cytotoxicity against human MM96L cells after 6 days by SRB assay	[PMID: 22880631]
NCI-H358	IC₅₀	> 40 μM Compound: Diosgenin	Antiproliferative activity against human NCI-H358 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human NCI-H358 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 35586422]
NCI-H460	IC₅₀	> 50 μM Compound: 1	Cytotoxicity against human NCI-H460 cells incubated for 24 hrs by MTT assay Cytotoxicity against human NCI-H460 cells incubated for 24 hrs by MTT assay	[PMID: 28606759]
NCI-H460	GI₅₀	1.6 μg/mL Compound: 7	Growth inhibition of human NCI-H460 cells after 48 hrs Growth inhibition of human NCI-H460 cells after 48 hrs	[PMID: 15921418]
NFF	IC₅₀	> 50 μg/mL Compound: 21	Cytotoxicity against human NFF cells after 6 days by SRB assay Cytotoxicity against human NFF cells after 6 days by SRB assay	[PMID: 22880631]
P388	ED₅₀	> 10 μg/mL Compound: 7	Growth inhibition of mouse P388 cells after 48 hrs Growth inhibition of mouse P388 cells after 48 hrs	[PMID: 15921418]
SF-268	GI₅₀	1.6 μg/mL Compound: 7	Growth inhibition of human SF268 cells after 48 hrs Growth inhibition of human SF268 cells after 48 hrs	[PMID: 15921418]
SMMC-7721	IC₅₀	> 20 μM Compound: a1	Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
SW480	IC₅₀	> 20 μM Compound: a1	Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
SW-620	IC₅₀	> 40 μM Compound: Diosgenin	Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 35586422]
T-24	IC₅₀	28.85 μM Compound: DSG; 1	Cytotoxicity against human T24 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against human T24 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 33740546]
THP-1	IC₅₀	6.96 μM Compound: 2	Anticoagulant activity in human THP1 cells assessed as inhibition of TNF-alpha-stimulated tissue factor expression incubated 1 hr before TNFalpha challenge measured after 5 hrs Anticoagulant activity in human THP1 cells assessed as inhibition of TNF-alpha-stimulated tissue factor expression incubated 1 hr before TNFalpha challenge measured after 5 hrs	[PMID: 20561785]

體外研究
(In Vitro)

在 MC65 細胞 (一種細胞 AD 模型) 中，Diosgenin 在 1 μM 時表現(xiàn)出較弱的保護能力，可能是抗 AD 病理學的二價化合物中作為甾體部分的良好候選者^[3]。Diosgenin 以劑量依賴性方式抑制 C3A 細胞中 STAT3 的組成型激活，最大抑制發(fā)生在 100 μM 左右^[1]。
Diosgenin (10 μM；24 h) 顯著降低泡沫細胞中 miR-19b 的水平^[5]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內研究
(In Vivo)

Diosgenin 顯著降低 HF 飲食喂養(yǎng)小鼠的禁食和再進食血糖水平。與 HF 飲食喂養(yǎng)的小鼠相比，Diosgenin 顯著降低 IPGTT 試驗中的血糖水平^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

414.62

Formula

C₂₇H₄₂O₃

CAS 號

512-04-9

性狀

固體

顏色

White to off-white

中文名稱

薯蕷皂素；薯蕷皂甙元；薯蕷皂苷元；地奧配質；薯芋皂苷配基；薯芋皂素

結構分類

Steroids

初始來源

運輸條件

Room temperature in continental US; may vary elsewhere.

儲存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性數(shù)據(jù)

細胞實驗：

Ethanol 中的溶解度 : 3.33 mg/mL (8.03 mM; 超聲助溶)

H₂O 中的溶解度 : < 0.1 mg/mL (insoluble)

DMSO 中的溶解度 : < 1 mg/mL (insoluble or slightly soluble)

配制儲備液

濃度溶劑體積質量	1 mg	5 mg	10 mg

1 mM	2.4118 mL	12.0592 mL	24.1185 mL
5 mM	0.4824 mL	2.4118 mL	4.8237 mL
10 mM	---	---	---

查看完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲存時，請在2年內使用， -20°C儲存時，請在1年內使用。

摩爾計算器
稀釋計算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動物實驗：

請根據(jù)您的實驗動物和給藥方式選擇適當?shù)娜芙夥桨浮?

以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
——為保證實驗結果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當保存；體內實驗的工作液，建議您現(xiàn)用現(xiàn)配，當天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

方案一

請依序添加每種溶劑： 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.67 mg/mL (1.62 mM); 澄清溶液

此方案可獲得 ≥ 0.67 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 6.7 mg/mL 的澄清 EtOH 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水定容至 1 mL。
生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
方案二

請依序添加每種溶劑： 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.67 mg/mL (1.62 mM); 澄清溶液

此方案可獲得 ≥ 0.67 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 6.7 mg/mL 的澄清 EtOH 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液中，混合均勻。
2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
方案三

請依序添加每種溶劑： 10% EtOH 90% Corn Oil
Solubility: ≥ 0.67 mg/mL (1.62 mM); 澄清溶液

此方案可獲得 ≥ 0.67 mg/mL（飽和度未知）的澄清溶液，此方案實驗周期在半個月以上的動物實驗酌情使用。
以 1 mL 工作液為例，取 100 μL 6.7 mg/mL 的澄清 EtOH 儲備液加到 900 μL 玉米油中，混合均勻。

以下溶解方案，請直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內盡快用完。以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

方案一

請依序添加每種溶劑： Corn Oil
Solubility: 2.5 mg/mL (6.03 mM); 懸濁液; 超聲助溶
方案二

請依序添加每種溶劑： 15% Solutol HS 15 10% Cremophor EL 35% PEG400 40% Water
Solubility: 10.31 mg/mL (24.87 mM); 懸濁液; 超聲助溶

動物溶解方案計算器

請輸入動物實驗的基本信息：

給藥劑量

mg/kg

動物的平均體重

每只動物的給藥體積

μL

動物數(shù)量

只

由于實驗過程有損耗，建議您多配一只動物的量

計算結果

工作液所需濃度 : mg/mL

純度 & 產(chǎn)品資料

純度: 99.35%

選擇批次：

Data Sheet (645 KB) SDS (393 KB)

COA (290 KB) HNMR (264 KB) RP-HPLC (253 KB) MS (83 KB)

產(chǎn)品使用指南 (1538 KB)

參考文獻

[1]. Li F, et al. Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells. Cancer Lett. 2010 Jun 28;292(2):197-207. [Content Brief]

[2]. Tohda C, et al. Diosgenin is an exogenous activator of 1,25D?-MARRS/Pdia3/ERp57 and improves Alzheimer's disease pathologies in 5XFAD mice. Sci Rep. 2012;2:535. [Content Brief]

[3]. Jeremy E. Chojnacki, et al. Bivalent ligands incorporating curcumin and diosgenin as multifunctional compounds against Alzheimer’s disease. Bioorganic & Medicinal Chemistry, 23 (2015) 7324–7331 [Content Brief]

[4]. Wang X, et al. Effect of diosgenin on metabolic dysfunction: Role of ERβ in the regulation of PPARγ. Toxicol Appl Pharmacol. 2015 Dec 1;289(2):286-96. [Content Brief]

[5]. Yun-cheng Lv, et al. Diosgenin Inhibits Atherosclerosis via Suppressing the MiR-19b-induced Downregulation of ATP-binding Cassette Transporter A1. Atherosclerosis, 2014, 240(1), 80-89.

Diosgenin 相關分類

Metabolic Disease

完整儲備液配制表

可選溶劑	濃度溶劑體積質量	1 mg	5 mg	10 mg	25 mg

Ethanol	1 mM	2.4118 mL	12.0592 mL	24.1185 mL	60.2962 mL
Ethanol	5 mM	0.4824 mL	2.4118 mL	4.8237 mL	12.0592 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Diosgenin512-04-9薯蕷皂素薯蕷皂甙元薯蕷皂苷元地奧配質薯芋皂苷配基薯芋皂素STATMicroRNAmiRNAInhibitorinhibitorinhibit

產(chǎn)品名稱：			* 需求量：
* 客戶姓名：			* Email：
* 電話：			* 公司或機構名稱：
留言給我們：

產(chǎn)品名稱：			* Lot #：
* 客戶姓名：			* Email：
電話：			* 部門：
* 公司或機構名稱：
留言給我們：

MedChemExpress (MCE) 只為有資質的科研機構、醫(yī)藥企業(yè)基于科學研究或藥證申報的用途提供醫(yī)藥研發(fā)服務，不為任何個人或者非科研性質的、非用于藥證申報使用等其他用途提供服務。	站點地圖隱私聲明
滬ICP備15051369號-4 上海工商滬公網(wǎng)安備31011502019417 滬(浦)應急管危經(jīng)許[2021]201709(QFYS) 營業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2025 MedChemExpress. All Rights Reserved.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Diosgenin (Synonyms: 薯蕷皂素)

Customer Review

Other Forms of Diosgenin:

MCE 顧客使用本產(chǎn)品發(fā)表的 5 篇科研文獻

Diosgenin 相關產(chǎn)品

•相關化合物庫:

•同靶點產(chǎn)品:

•同靶點蛋白產(chǎn)品:

查看 STAT 亞型特異性產(chǎn)品:

生物活性

純度 & 產(chǎn)品資料

參考文獻

摩爾計算器

稀釋計算器

Diosgenin 相關分類

完整儲備液配制表

Keywords:

您最近查看的產(chǎn)品:

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
郵箱 *

Sorry, but the email address you supplied was invalid.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Diosgenin (Synonyms: 薯蕷皂素)

Customer Review

Other Forms of Diosgenin:

Diosgenin 相關抗體

MCE 顧客使用本產(chǎn)品發(fā)表的 5 篇科研文獻

Diosgenin 相關產(chǎn)品

•相關化合物庫:

•同靶點產(chǎn)品:

•同靶點蛋白產(chǎn)品:

查看 STAT 亞型特異性產(chǎn)品:

生物活性

純度 & 產(chǎn)品資料

參考文獻

Diosgenin 相關抗體:

摩爾計算器

稀釋計算器

Diosgenin 相關分類

完整儲備液配制表

Keywords:

您最近查看的產(chǎn)品:

Request for HNMR Report

Request for HNMR Report

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z